Skip to Content Skip to Navigation

About us Practical matters How to find us prof. dr. G.N. (Gert) Moll

prof. dr. G.N. (Gert) Moll

Department of Molecular Genetics, GBB

No picture available

Faculty of Science and Engineering

Telephone:

+31 50 36 32111

E-mail:

g.n.moll rug.nl

ORCID Research Portal

Publications

Advances in the therapeutic potentials of ligands of the apelin receptor APJ

Wagenaar, G. T. M. & Moll, G. N., 15-Mar-2025, In: European Journal of Pharmacology. 14 p., 177302.

Research output: Contribution to journal › Review article › peer-review

Clinical significance of intervention in the renin-angiotensin-aldosterone-apelinergic system

Wagenaar, G. T. M. & Moll, G. N., 15-Sept-2025, In: European Journal of Pharmacology. 1003, 11 p., 177866.

Research output: Contribution to journal › Review article › peer-review

Agonists of galanin subtype 2 receptor may prevent pancreatic cancer and agonists of angiotensin II type 2 receptor may prevent colorectal cancer

Moll, G. N., 5-Sept-2024, In: European Journal of Pharmacology. 978, 8 p., 176772.

Research output: Contribution to journal › Review article › peer-review

AT2 receptor agonist LP2 restores respiratory function in a rat model of bleomycin-induced lung remodelling

Villela, D. C., Namsolleck, P., Reichetzeder, C. & Moll, G. N., 2023, In: Peptides. 170, 9 p., 171106.

Research output: Contribution to journal › Article › Academic › peer-review

Evolving views on the first two ligands of the angiotensin II type 2 receptor. From putative antagonists to potential agonists?

Wagenaar, G. T. M. & Moll, G. N., 15-Dec-2023, In: European Journal of Pharmacology. 961, 8 p., 176189.

Research output: Contribution to journal › Review article › peer-review

Galanin 2 Receptor: A Novel Target for a Subset of Pancreatic Ductal Adenocarcinoma

Namsolleck, P., Kofler, B. & Moll, G. N., 15-Jun-2023, In: International Journal of Molecular Sciences. 24, 12, 9 p., 10193.

Research output: Contribution to journal › Article › Academic › peer-review

LP2, a cyclic angiotensin-(1−7) analog extended with an N-terminal D-lysine, impairs growth of patient-derived xenografts of colorectal carcinoma in mice

Namsolleck, P., de Vries, L. & Moll, G. N., Feb-2023, In: Peptides. 160, 170920.

Research output: Contribution to journal › Article › Academic › peer-review

LP2, a stable lanthipeptide derived from cAng-(1-7), exerts myeloprotective action in mice

Namsolleck, P., Rodgers, K. E., Franklin, R. & Moll, G. N., May-2023, In: European Journal of Haematology. 110, 5, p. 534-539 6 p.

Research output: Contribution to journal › Article › Academic › peer-review

Intranasal Delivery of a Methyllanthionine-Stabilized Galanin Receptor-2-Selective Agonist Reduces Acute Food Intake

Kuipers, A., Balaskó, M., Pétervári, E., Koller, A., Brunner, S. M., Moll, G. N. & Kofler, B., Oct-2021, In: Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics. 18, p. 2737–2752 16 p.

Research output: Contribution to journal › Article › Academic › peer-review

LP2, the first lanthipeptide GPCR agonist in a human pharmacokinetics and safety study

Namsolleck, P., Richardson, A., Moll, G. N. & Mescheder, A., Feb-2021, In: Peptides. 136, 170468.

Research output: Contribution to journal › Article › Academic › peer-review

All (68) publications

Press/media

Uit RUG voortgekomen Lanthio Pharma Chemische Start-up van het Jaar

Moll, G.

24/11/2014

Press/Media: Public Engagement Activities › Popular

All (1) press/media

View full research profile

Follow the UGfacebook linkedin rss instagram youtube